Interview with Dr. Arya Sharma on Obesity and Pharmaceutical Management

Introduction

Clinical Trials Canada magazine editor Saaqshi Sharma recently spoke with bariatric researcher and physician Dr. Arya Sharma to explore the complexities of obesity and the evolving role of pharmaceuticals in managing this chronic condition.

Role of Pharmaceuticals in Obesity Management

Saaqshi Sharma: Dr. Sharma, could you elaborate on the significance of pharmaceuticals in the treatment of obesity?

Arya Sharma: Research indicates that diet and lifestyle changes typically lead to modest weight loss, averaging around 3-5% of initial body weight. While this level of weight loss offers notable health benefits—such as a 60% reduction in diabetes risk from a 5% weight decrease—many individuals require greater weight loss. This is where pharmacotherapy becomes relevant; however, there are currently limited pharmaceutical options available for obesity management.

Challenges in Developing Obesity Pharmaceuticals

Saaqshi Sharma: Why do you think there are so few pharmaceutical treatments for obesity?

Arya Sharma: Treating obesity is inherently challenging due to numerous biological mechanisms that hinder weight loss and encourage weight regain. The body actively resists weight loss, and only a few drugs can effectively interact with this complex system. Furthermore, many previous drugs that aimed to suppress appetite or increase calorie expenditure were withdrawn from the market due to adverse side effects.

Qnexa: A New Hope in Obesity Treatment

Saaqshi Sharma: The FDA is currently reviewing a new obesity drug called Qnexa, for which you have consulted. What sets Qnexa apart from other treatments?

Arya Sharma: Qnexa is unique because it combines two established medications: phentermine, a widely used appetite suppressant, and topiramate, initially developed as an anti-epileptic drug and now also prescribed for migraine prevention. Given that both components have been on the market for years, we have insights into their long-term effects and mechanisms. It’s essential to weigh the potential side effects of obesity drugs against the risks associated with untreated obesity, which can lead to serious health complications. Due to potential risks for pregnant women, Qnexa will likely be dispensed through controlled pharmacy access, accompanied by educational programs for women of childbearing age.

Patient Perspectives on New Treatments

Saaqshi Sharma: As a bariatric specialist, do you believe that patients share your optimism regarding this new development? Are they advocating for such treatments?

Arya Sharma: There is undoubtedly a significant treatment gap in obesity management. While diet and exercise may lead to a 3-5% weight loss and bariatric surgery can achieve around 20%, the options in between are limited. Many patients struggle to maintain weight loss independently and are seeking additional treatment alternatives. Just as with other chronic conditions like hypertension and diabetes, a single drug may not be effective for everyone. Given that obesity is a chronic issue, an effective medication must not only facilitate weight loss but also assist in weight maintenance over the long term. Increased options for patients can enhance the likelihood of sustained weight loss.

Final Thoughts on Obesity Treatment

Saaqshi Sharma: Is there anything else you wish to convey to our readers?

Arya Sharma: It is crucial to view obesity as a chronic condition and understand that there is no straightforward solution. Obesity often serves as a root cause for other health issues, and effectively treating it can significantly alleviate various related problems. This is a matter that warrants attention and support from all stakeholders involved in healthcare.